# Avanos Medical share price (Avanos Medical, Inc., AVNS)

> Avanos Medical, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AVNS · Healthcare · Medical Devices · data as of 24 July 2026. Page: https://www.sectoralpha.in/us/stocks/avns

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $24.99 (+108.1% in a year)
- Revenue (Mar 2026): $182 M (+8.8% on a year ago)
- Profit (Mar 2026): $5.1 M (−22.7% on a year ago)
- Operating margin: 5.4% (+0.1 points on a year ago)
- ROE: −9%, FY25
- ROIC: 2.0%, against a 12.0% cost of capital: −10.0 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Avanos Medical share price? Avanos Medical, Inc.'s share price was $24.99 at the close on 24 July 2026. That is 47.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $11 and $25, and at that close it was at the high of that range. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 2 weeks running. Over the last 1 year the share price moved +109% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 10 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Avanos Medical pay? Avanos Medical, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Avanos Medical on? Avanos Medical is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Avanos Medical profitable? Avanos Medical, Inc. earned $5.1 M of net profit in the Mar 2026 quarter, −22.7% on the same quarter a year earlier. The full FY25 year was a loss of $72.9 M. That is 2.8% of the quarter's revenue. The same quarter a year earlier earned $6.6 M. 7 of the last 12 reported quarters were loss-making. Why profit moved: revenue changed +8.8% on a year earlier and the margin moved +0.1 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −1,507.3% and revenue +3.9%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Avanos Medical make, and is it growing? Avanos Medical, Inc. reported $182 M of revenue in the Mar 2026 quarter, +8.8% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 4 years it has grown 4.5% a year on average. The last full year, FY25, came in at $701 M. The last four reported quarters add to $716 M. FY25 revenue was $701 M, +1.9% on the year before. Recent pace: the last four quarters grew +3.9% on average, against 4.5% a year over the longer run, so this year is growing at about the same pace as its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.9%, against +2.6% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Avanos Medical keep? Avanos Medical, Inc.'s operating margin was 5.4% in the Mar 2026 quarter, 0.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between 0.7% and 5.2%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +0.1 percentage points on the year while gross margin changed −1.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Avanos Medical's profit turning into cash? Over the last 2 years, 314% of Avanos Medical, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $74.7 M of operating cash against −$72.9 M of profit. After $31.6 M of spending on assets, $43.1 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Avanos Medical's cash go? Avanos Medical, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $67.2 M on assets over the last 3 years. Averaged over those years that is 3.2% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $67.2 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Avanos Medical's P/E ratio, and how does it compare with its own history? Avanos Medical, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Avanos Medical, Inc. at 1.7× its FY25 revenue of $701 M. The P/E comes back here once profit turns positive. ## Is the Avanos Medical business getting better or worse? Avanos Medical, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Avanos Medical earn on its capital? Avanos Medical, Inc. earned a ROE of −9% in FY25. That is up from a low of −47% in FY24. Its return on capital used (ROIC) is 10.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −10.4% net margin and 0.65× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −10.4% net margin × 0.65× asset turnover × 1.38× leverage (assets divided by equity) ≈ −9.3% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 2.0% − 12.0% = −10.0 percentage points. The 12.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Avanos Medical have too much debt? Avanos Medical, Inc. has total debt of $138 M against shareholder equity of $782 M as of Mar 2026, so its debt is 0.18× its equity, which is very little. Year by year, that ratio went from 0.15 in FY21 to 0.17 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Avanos Medical shareholding pattern? 3.8% of Avanos Medical, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Avanos Medical from balance-sheet trouble? For Avanos Medical, Inc., the Z-score is 1.20. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.20 is inside the danger zone, so the balance sheet is a real risk. ## How does Avanos Medical rank in its industry? There is no score against its industry: Avanos Medical, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Avanos Medical compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Avanos Medical in size? Avanos Medical is the 33rd largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: CONMED Corporation, Tandem Diabetes Care, Inc. and Enovis Corporation. Just below it: Alphatec Holdings, Inc., Artivion, Inc. and PROCEPT BioRobotics Corporation. ### Medical Devices companies close in size

1. [CONMED Corporation](https://www.sectoralpha.in/us/stocks/cnmd) $1.4 billion
2. [Tandem Diabetes Care, Inc.](https://www.sectoralpha.in/us/stocks/tndm) $1.2 billion
3. [Enovis Corporation](https://www.sectoralpha.in/us/stocks/enov) $1.2 billion
4. Avanos Medical, Inc. $1.2 billion
5. [Alphatec Holdings, Inc.](https://www.sectoralpha.in/us/stocks/atec) $1.2 billion
6. [Artivion, Inc.](https://www.sectoralpha.in/us/stocks/aort) $1.2 billion
7. [PROCEPT BioRobotics Corporation](https://www.sectoralpha.in/us/stocks/prct) $1.2 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [MannKind Corporation](https://www.sectoralpha.in/us/stocks/mnkd) $1.2 billion · Biotechnology
2. [Tennant Company](https://www.sectoralpha.in/us/stocks/tnc) $1.2 billion · Specialty Industrial Machinery
3. Avanos Medical, Inc. $1.2 billion
4. [Gold.com, Inc.](https://www.sectoralpha.in/us/stocks/gold) $1.2 billion · Capital Markets
5. [Syndax Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/sndx) $1.2 billion · Biotechnology

## What else do people ask about Avanos Medical? ### What were Avanos Medical's latest quarterly results? Avanos Medical, Inc. reported revenue of $182 M and net profit of $5.1 M for the Mar 2026 quarter. Revenue rose 8.8% and profit fell 22.7% compared with a year earlier. Earnings per share were $0.11. The operating margin was 5.4%, 0.1 percentage points higher than a year earlier (as of 24 July 2026). ### What is Avanos Medical's market cap? Avanos Medical, Inc.'s market capitalisation is $1.2 B at a stock price of $24.99. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 24 July 2026). ### How is Avanos Medical performing? Avanos Medical, Inc.'s latest readings are below. In its latest quarter, revenue rose 8.8% and profit fell 22.7% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 2 weeks running. This describes what the data did, not a rating (as of 24 July 2026). ### Will Avanos Medical's stock price go up? This page does not forecast Avanos Medical, Inc.'s stock price. What it shows instead: the stock price is $24.99. Nobody can reliably say which way a price will move, and this site does not try (as of 24 July 2026). ### Is Avanos Medical's profit real cash? Yes, over the last 2 years, 314% of Avanos Medical, Inc.'s reported profit came in as cash from operations. The latest year was lower at -102%, so the trend is worth watching. In FY25, operating cash was $74.7 M against reported profit of −$72.9 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 24 July 2026). ### Where is Avanos Medical in its business cycle? Avanos Medical, Inc.'s FY25 operating margin was 2.2%, against a 5-year range of 0.7% to 5.2%: the middle of its own range, neither a peak nor a low. The latest quarter was 5.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 24 July 2026). ### What could break the Avanos Medical story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 24 July 2026). ### Is Avanos Medical a stock worth studying right now? What the numbers show: Avanos Medical, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 24 July 2026). This is research, not advice. We’re not SEBI-registered.